View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsKaro Pharma 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長21.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 06Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million on December 5, 2022. Decubal, Lactocare, Apobase, Flux, Dailycare and Fludent, which are primarily sold in the Nordics. The acquisition is expected to be final on 1 April, 2023. The annual turnover for the acquired brands is DKK 330 million.お知らせ • Nov 11+ 1 more updateNasdaq Approves Karo Pharma's Application for De-ListingKaro Pharma AB (publ) ("Karo Pharma Aktiebolag", "Karo Pharma" or the "Company") application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma's share on Nasdaq First North Growth Market will be 24 November 2022. As previously announced, Karo Pharma has applied for de-listing of the Company's shares from Nasdaq First North Growth Market. Nasdaq has now approved the application and resolved that the last day of trading will be November 24, 2022.お知らせ • Aug 17Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion on August 16, 2022. Karo Intressenter offered SEK 60 cash per share to acquire 37,231,505 remaining shares of Karo Pharma. As of date of this offer, Karo Intressenter holds 236,023,099 shares in Karo Pharma, corresponding to 86.4%. The consideration payable in respect of the offer is financed in full by funds available to Karo Intressenter by way of an equity commitment letter issued by EQT VIII. Karo Intressenter does not intend to implement any material changes that may impact Karo Pharma’s employees and management, nor to its existing organization and operations, including the terms of employment and the locations where Karo Pharma conducts its business. Completion of the offer is conditional upon the offer being accepted to such extent that Karo Intressenter becomes the owner of shares representing more than 90% of the total number of outstanding shares in Karo Pharma. In the event that Karo Intressenter obtains more than 90% of the outstanding shares in Karo Pharma, it intends to initiate compulsory redemption proceedings under the Swedish Companies Act to acquire all remaining shares in Karo Pharma. The acceptance period for the offer is expected to commence on August 18, 2022 and expire on September 15, 2022. SEB Corporate Finance, Skandinaviska Enskilda Banken AB is financial advisor and White & Case is legal advisor to Karo Intressenter in connection with the offer. Roschier Advokatbyrå AB has been appointed as legal advisor of Karo Pharma.お知らせ • Apr 03Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).Karo Pharma AB (publ) (OM:KARO) entered into an agreement to acquire E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) for an implied enterprise value of £200 million on December 24, 2021. The Proposed Sale, if completed, would be another step forward in Reckitt’s plan to actively manage its portfolio for higher growth, following the recent divestments of its IFCN business in China and its Scholl brand, as well as the acquisition of Biofreeze. The transaction is expected to close in the second quarter of 2022. As of April 1, 2022. All conditions to the completion of the transaction have been satisfied. Matthew Appleton, Gareth Irving, Lydia Challen and Alasdair Balfour of Allen & Overy LLP acted as legal advisor to Reckitt Benckiser Group plc. Centerview Partners UK LLP acted as financial advisor to Reckitt Benckiser Group plc . Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) on April 1, 2022.お知らせ • Mar 28Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022Karo Pharma AB (publ) announced that they will report fiscal year 2021 final results on Apr 12, 2022Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.08 loss per share (down from kr0.37 profit in FY 2020). Revenue: kr2.96b (up 2.7% from FY 2020). Net loss: kr17.5m (down 121% from profit in FY 2020). Revenue missed analyst estimates by 2.3%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.お知らせ • Feb 26+ 1 more updateKaro Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022Karo Pharma AB (publ) announced that they will report nine months, 2022 results on Oct 25, 2022お知らせ • Feb 16+ 1 more updateKaro Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022Karo Pharma AB (publ) announced that they will report fiscal year 2021 results at 2:00 PM, Central European Standard Time on Feb 25, 2022お知らせ • Jan 14Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders. Robin List, Chief Executive Officer of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, Chief Executive Officer. Robin shall continue to manage the Sylphar businesses and will be instrumental in the integration and forward operations of the combined companies. For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods. Ola Sandersson and Malin Leffler of Roschier acted as legal advisors for Vendis Capital and Robin List. Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others on January 13, 2021.お知らせ • Nov 24Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders. For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr738.5m (up 8.7% from 3Q 2020). Net income: kr59.0m (up kr61.8m from 3Q 2020). Profit margin: 8.0% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 129 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr747.9m (up 8.6% from 2Q 2020). Net loss: kr21.4m (down 184% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.お知らせ • Jul 03Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021. The portfolio had a turnover of SEK 62 million in 2020. Evolan Pharma AB completed the acquisition of Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021.Executive Departure • Apr 27Independent Chairman of the Board Bo Hansen has left the companyOn the 21st of April, Bo Hansen's tenure as Independent Chairman of the Board ended after 2.2 years in the role. We don't have any record of a personal shareholding under Bo's name. A total of 2 executives have left over the last 12 months.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr713.0m (down 10% from 1Q 2020). Net income: kr53.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 11% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 02Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Feb 17Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021, at 15:00 Central European Standard Time. Location: Näringslivets Hus Stockholm Swedenお知らせ • Feb 04Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million on February 3, 2021. European OTC brand portfolio comprises of Flux, Decubal, Lactocare, Apobase, Dailycare and Fludent. For the year ended 2020, European OTC brand portfolio reported a revenue of €35 million. The transaction is financed with existing cash and is expected to close on April 1, 2021.Is New 90 Day High Low • Jan 27New 90-day low: €4.81The company is down 24% from its price of €6.32 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.Is New 90 Day High Low • Jan 08New 90-day low: €5.08The company is down 25% from its price of €6.80 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.お知らせ • Dec 26+ 3 more updatesKaro Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021Karo Pharma AB (publ) announced that they will report first half, 2021 results on Jul 22, 2021Is New 90 Day High Low • Dec 22New 90-day low: €5.38The company is down 20% from its price of €6.74 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Dec 05New 90-day low: €5.87The company is down 7.0% from its price of €6.28 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.お知らせ • Nov 18J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million on November 16, 2020. Swereco AB reported revenues of SEK 118 million on December 31, 2019. The transaction is expected to close in December 1, 2020.Reported Earnings • Nov 05Third quarter 2020 earnings released: kr0.013 loss per shareThe company reported a mediocre third quarter result with increased losses, although revenues were improved. Third quarter 2020 results: Revenue: kr679.1m (up 53% from 3Q 2019). Net loss: kr2.76m (loss widened 53% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr86.1m, up 46% from the prior year. Total revenue was kr2.81b over the last 12 months, up 64% from the prior year.お知らせ • Sep 29+ 1 more updateEQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.EQT VIII, a fund managed by EQT Partners AB made a public offer to acquire Karo Pharma AB (publ) (OM:KARO) for SEK 6 billion on October 29, 2018. Under the terms of the transaction, EQT will pay a cash consideration of SEK 36.90 in cash per Karo Pharma share. On January 2, 2019, EQT VIII, a fund managed by EQT Partners AB increases the offer price to SEK 38 per share for a total consideration of SEK 6.2 billion. The purchase price is fully financed through equity from EQT VIII. EQT proposes that the Board of Directors shall consist of six Board Members without any deputies, that the Board Member Håkan Åström is reelected, and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board. Bo Jesper Hansen indicated that due to his other assignments, would be willing to serve as interim Chairman of the Board until the end of the next Annual General Meeting, after which he would be available for a position as ordinary board member and vice Chairman of the Board. Marianne Hamilton, Thomas Hedner and Per-Anders Johansson will resign, and the Board of Directors will therefore, in case the Extraordinary General Meeting resolves in accordance with the proposal, consist of Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen, Åsa Riisberg and Håkan Åström until the end of the next Annual General Meeting. Anders Lönner, Executive Chairman of the Company's Board of Directors, and Per-Anders Johansson, member of the Karo’s Board of Directors, together holding 21.9 million shares in Karo Pharma representing in total approximately 13.6% of the outstanding shares and votes in Karo, have expressed their support for the offer and declared that they intend to accept the offer. In the event that EQT Partners obtains more than 90% of the outstanding shares in Karo Pharma, it intends to initiate a compulsory acquisition procedure under the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) of Karo Pharma. EQT Partners intends to promote a delisting of the Karo Pharma shares from Nasdaq Stockholm. The transaction is conditional upon customary conditions, inter alia, being accepted to such an extent that EQT becomes the owner of more than 90% of the total number of the outstanding shares in Karo Pharma as well as the receipt of all necessary regulatory or similar clearances, approvals and decisions, including from competition authorities, in each case on terms which, in EQT’s opinion, are acceptable. EQT has reserved the right to waive this and other completion conditions according to the offer. The transaction is not conditional upon financing. The transaction has been unanimously approved by the Board of Directors of Karo Pharma. The tender offer is expected to commence on November 13, 2018 and end of December 10, 2018. As of December 13, 2018, EQT Partners extended the offer period until January 4, 2019. As of January 2, 2019, EQT Partners extended the offer period until January 17, 2019. At the end of the extended acceptance period on January 17, 2019, the shares in Karo Pharma tendered in the offer at the end of the extended acceptance period on January 17, 2019, together with the shares in Karo Pharma acquired by EQT Partners on the market, correspond to approximately 62.8% of the total number of outstanding shares and votes in Karo Pharma. EQT waived the condition regarding a minimum level of acceptance in the offer. Furthermore, all other conditions for completion of the offer have been satisfied and the offer is now unconditional. The acceptance period for the offer is extended up to and including February 12, 2019 to allow remaining shareholders in Karo Pharma to accept the Offer. Hamilton Advokatbyrå acted as legal advisor while Deloitte AB provided fairness opinion to Karo Pharma. Skandinaviska Enskilda Banken AB (publ.) acted as financial advisor and Jan Jensen, Rikard Stenberg, Johan Thiman, Oscar Liljeson, Peter Svanqvist, Patrik Erblad, David Riihonen, Erik Larsson, Rebecka Tenenbaum, Anders Westling, Petar Bojovic, Gustaf Wiklund and Björn Torsteinsrud of White & Case acted as legal advisors to EQT Partners in connection with the transaction. EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion in January, 2019.お知らせ • Jul 31+ 1 more updateKaro Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million on May 8, 2020. The transaction is financed by a new loan facility from SEB, Swedbank and DNB NOR. The remaining Pevaryl® brand portfolio generated net sales of around €20 million in 2019. The transaction gives full control to Karo Pharma AB for the Pevaryl® brand portfolio in Europe. No personnel or manufacturing sites are included in the agreement and the technology transfer risks are limited. Johnson & Johnson and Karo Pharma will collaborate to secure a seamless transfer of the portfolio, including relevant approvals. Sawaya Partners, LLC acted as the financial advisor for Karo Pharma AB (publ). Karo Pharma AB (publ) (OM:KARO) completed the acquisition of remaining Pevaryl® brand portfolio from Cilag GmbH International on May 8, 2020.お知らせ • Jul 21Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021Karo Pharma AB (publ) announced that they will report fiscal year 2020 results on Feb 18, 2021 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Karo Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:KA6N - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20223,466-190-2,050507N/A3/31/20223,231-141-1,546572N/A12/31/20212,961-17-290533N/A9/30/20212,92163-464377N/A6/30/20212,8612-575340N/A3/31/20212,80249-350373N/A12/31/20202,88382-1,365329N/A9/30/20202,81186-1,410214N/A6/30/20202,57587-1,56165N/A3/31/20202,27455-9525N/A12/31/20191,9019122107N/A9/30/20191,71560107146N/A6/30/20191,667117353385N/A3/31/20191,769650343368N/A12/31/20181,615657299318N/A9/30/20181,391595252261N/A6/30/20181,1325518292N/A3/31/2018785403140N/A12/31/2017658152634N/A9/30/20175151416872N/A6/30/20174631337684N/A3/31/2017404114-1060N/A12/31/201634796-106-36N/A9/30/2016308-20-119-51N/A6/30/2016232-41-125-62N/A3/31/2016151-60N/A-94N/A12/31/201569-78N/A-52N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KA6Nの予測収益成長が 貯蓄率 ( 0.03% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: KA6Nの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: KA6Nの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: KA6Nの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: KA6Nの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KA6Nの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/11/27 23:21終値2022/11/24 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Karo Pharma AB (publ) これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Camilla OxhamreCarnegie Investment Bank ABOlle SjölinNordea MarketsPeter AbelinRedeye
お知らせ • Dec 06Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million on December 5, 2022. Decubal, Lactocare, Apobase, Flux, Dailycare and Fludent, which are primarily sold in the Nordics. The acquisition is expected to be final on 1 April, 2023. The annual turnover for the acquired brands is DKK 330 million.
お知らせ • Nov 11+ 1 more updateNasdaq Approves Karo Pharma's Application for De-ListingKaro Pharma AB (publ) ("Karo Pharma Aktiebolag", "Karo Pharma" or the "Company") application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma's share on Nasdaq First North Growth Market will be 24 November 2022. As previously announced, Karo Pharma has applied for de-listing of the Company's shares from Nasdaq First North Growth Market. Nasdaq has now approved the application and resolved that the last day of trading will be November 24, 2022.
お知らせ • Aug 17Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion on August 16, 2022. Karo Intressenter offered SEK 60 cash per share to acquire 37,231,505 remaining shares of Karo Pharma. As of date of this offer, Karo Intressenter holds 236,023,099 shares in Karo Pharma, corresponding to 86.4%. The consideration payable in respect of the offer is financed in full by funds available to Karo Intressenter by way of an equity commitment letter issued by EQT VIII. Karo Intressenter does not intend to implement any material changes that may impact Karo Pharma’s employees and management, nor to its existing organization and operations, including the terms of employment and the locations where Karo Pharma conducts its business. Completion of the offer is conditional upon the offer being accepted to such extent that Karo Intressenter becomes the owner of shares representing more than 90% of the total number of outstanding shares in Karo Pharma. In the event that Karo Intressenter obtains more than 90% of the outstanding shares in Karo Pharma, it intends to initiate compulsory redemption proceedings under the Swedish Companies Act to acquire all remaining shares in Karo Pharma. The acceptance period for the offer is expected to commence on August 18, 2022 and expire on September 15, 2022. SEB Corporate Finance, Skandinaviska Enskilda Banken AB is financial advisor and White & Case is legal advisor to Karo Intressenter in connection with the offer. Roschier Advokatbyrå AB has been appointed as legal advisor of Karo Pharma.
お知らせ • Apr 03Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).Karo Pharma AB (publ) (OM:KARO) entered into an agreement to acquire E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) for an implied enterprise value of £200 million on December 24, 2021. The Proposed Sale, if completed, would be another step forward in Reckitt’s plan to actively manage its portfolio for higher growth, following the recent divestments of its IFCN business in China and its Scholl brand, as well as the acquisition of Biofreeze. The transaction is expected to close in the second quarter of 2022. As of April 1, 2022. All conditions to the completion of the transaction have been satisfied. Matthew Appleton, Gareth Irving, Lydia Challen and Alasdair Balfour of Allen & Overy LLP acted as legal advisor to Reckitt Benckiser Group plc. Centerview Partners UK LLP acted as financial advisor to Reckitt Benckiser Group plc . Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) on April 1, 2022.
お知らせ • Mar 28Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022Karo Pharma AB (publ) announced that they will report fiscal year 2021 final results on Apr 12, 2022
Reported Earnings • Feb 26Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr0.08 loss per share (down from kr0.37 profit in FY 2020). Revenue: kr2.96b (up 2.7% from FY 2020). Net loss: kr17.5m (down 121% from profit in FY 2020). Revenue missed analyst estimates by 2.3%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 26+ 1 more updateKaro Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022Karo Pharma AB (publ) announced that they will report nine months, 2022 results on Oct 25, 2022
お知らせ • Feb 16+ 1 more updateKaro Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022Karo Pharma AB (publ) announced that they will report fiscal year 2021 results at 2:00 PM, Central European Standard Time on Feb 25, 2022
お知らせ • Jan 14Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders. Robin List, Chief Executive Officer of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, Chief Executive Officer. Robin shall continue to manage the Sylphar businesses and will be instrumental in the integration and forward operations of the combined companies. For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods. Ola Sandersson and Malin Leffler of Roschier acted as legal advisors for Vendis Capital and Robin List. Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others on January 13, 2021.
お知らせ • Nov 24Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million on November 22, 2021. Under the terms, €290 million will be paid on a cash and debt free basis and a minor additional payment amounting to €10 million may be paid if certain conditions are met in relation to future growth targets for the Sylphar Group. Acquisition also includes the direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (Pro Teeth Whitening), Nutravita Limited (Nutravita) and Alpha Foods BV (Alpha Food), together the Sylphar Group. As part of the transaction, Robin List and its management team as well as the former shareholders of Nutravita and Alpha Foods will reinvest in Karo Pharma. The acquisition will be financed by way of additional credit facilities, including an equity bridge loan facility with a tenor of twelve (12) months, which will be provided by certain of the Karo's existing bank lenders. For the year ended September 2021, Sylphar International generated sales of approximately €64 million. The transaction is subject to customary competition authority approvals being received. The transaction is expected to be completed during January 2022. Transaction is expected to contribute positively to Karo's market position and further enhance Karo's strong platform for continued growth, particularly in the digital marketplace. Jan Jensen, Patrik Erblad, Tilman Kuhn, Johan Thiman and Oscar Liljeson, Thomas Glauden, Peter Svanqvis of White & Case Advokat AB acted as legal advisor to Karo Pharma AB. Rothschild & Co SCA acted as financial advisor and Argo - BE acted as legal advisor to Vendis Capital, Robin List and the shareholders of Nutravita and Alpha Foods.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr738.5m (up 8.7% from 3Q 2020). Net income: kr59.0m (up kr61.8m from 3Q 2020). Profit margin: 8.0% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 129 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 23Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)The company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: kr747.9m (up 8.6% from 2Q 2020). Net loss: kr21.4m (down 184% from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 03Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021. The portfolio had a turnover of SEK 62 million in 2020. Evolan Pharma AB completed the acquisition of Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO) on July 1, 2021.
Executive Departure • Apr 27Independent Chairman of the Board Bo Hansen has left the companyOn the 21st of April, Bo Hansen's tenure as Independent Chairman of the Board ended after 2.2 years in the role. We don't have any record of a personal shareholding under Bo's name. A total of 2 executives have left over the last 12 months.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr713.0m (down 10% from 1Q 2020). Net income: kr53.3m (down 39% from 1Q 2020). Profit margin: 7.5% (down from 11% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 02Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 20Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr2.88b (up 52% from FY 2019). Net income: kr82.0m (up kr73.2m from FY 2019). Profit margin: 2.8% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Feb 17Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021, at 15:00 Central European Standard Time. Location: Näringslivets Hus Stockholm Sweden
お知らせ • Feb 04Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million on February 3, 2021. European OTC brand portfolio comprises of Flux, Decubal, Lactocare, Apobase, Dailycare and Fludent. For the year ended 2020, European OTC brand portfolio reported a revenue of €35 million. The transaction is financed with existing cash and is expected to close on April 1, 2021.
Is New 90 Day High Low • Jan 27New 90-day low: €4.81The company is down 24% from its price of €6.32 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
Is New 90 Day High Low • Jan 08New 90-day low: €5.08The company is down 25% from its price of €6.80 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
お知らせ • Dec 26+ 3 more updatesKaro Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021Karo Pharma AB (publ) announced that they will report first half, 2021 results on Jul 22, 2021
Is New 90 Day High Low • Dec 22New 90-day low: €5.38The company is down 20% from its price of €6.74 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Dec 05New 90-day low: €5.87The company is down 7.0% from its price of €6.28 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
お知らせ • Nov 18J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million on November 16, 2020. Swereco AB reported revenues of SEK 118 million on December 31, 2019. The transaction is expected to close in December 1, 2020.
Reported Earnings • Nov 05Third quarter 2020 earnings released: kr0.013 loss per shareThe company reported a mediocre third quarter result with increased losses, although revenues were improved. Third quarter 2020 results: Revenue: kr679.1m (up 53% from 3Q 2019). Net loss: kr2.76m (loss widened 53% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr86.1m, up 46% from the prior year. Total revenue was kr2.81b over the last 12 months, up 64% from the prior year.
お知らせ • Sep 29+ 1 more updateEQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.EQT VIII, a fund managed by EQT Partners AB made a public offer to acquire Karo Pharma AB (publ) (OM:KARO) for SEK 6 billion on October 29, 2018. Under the terms of the transaction, EQT will pay a cash consideration of SEK 36.90 in cash per Karo Pharma share. On January 2, 2019, EQT VIII, a fund managed by EQT Partners AB increases the offer price to SEK 38 per share for a total consideration of SEK 6.2 billion. The purchase price is fully financed through equity from EQT VIII. EQT proposes that the Board of Directors shall consist of six Board Members without any deputies, that the Board Member Håkan Åström is reelected, and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board. Bo Jesper Hansen indicated that due to his other assignments, would be willing to serve as interim Chairman of the Board until the end of the next Annual General Meeting, after which he would be available for a position as ordinary board member and vice Chairman of the Board. Marianne Hamilton, Thomas Hedner and Per-Anders Johansson will resign, and the Board of Directors will therefore, in case the Extraordinary General Meeting resolves in accordance with the proposal, consist of Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen, Åsa Riisberg and Håkan Åström until the end of the next Annual General Meeting. Anders Lönner, Executive Chairman of the Company's Board of Directors, and Per-Anders Johansson, member of the Karo’s Board of Directors, together holding 21.9 million shares in Karo Pharma representing in total approximately 13.6% of the outstanding shares and votes in Karo, have expressed their support for the offer and declared that they intend to accept the offer. In the event that EQT Partners obtains more than 90% of the outstanding shares in Karo Pharma, it intends to initiate a compulsory acquisition procedure under the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) of Karo Pharma. EQT Partners intends to promote a delisting of the Karo Pharma shares from Nasdaq Stockholm. The transaction is conditional upon customary conditions, inter alia, being accepted to such an extent that EQT becomes the owner of more than 90% of the total number of the outstanding shares in Karo Pharma as well as the receipt of all necessary regulatory or similar clearances, approvals and decisions, including from competition authorities, in each case on terms which, in EQT’s opinion, are acceptable. EQT has reserved the right to waive this and other completion conditions according to the offer. The transaction is not conditional upon financing. The transaction has been unanimously approved by the Board of Directors of Karo Pharma. The tender offer is expected to commence on November 13, 2018 and end of December 10, 2018. As of December 13, 2018, EQT Partners extended the offer period until January 4, 2019. As of January 2, 2019, EQT Partners extended the offer period until January 17, 2019. At the end of the extended acceptance period on January 17, 2019, the shares in Karo Pharma tendered in the offer at the end of the extended acceptance period on January 17, 2019, together with the shares in Karo Pharma acquired by EQT Partners on the market, correspond to approximately 62.8% of the total number of outstanding shares and votes in Karo Pharma. EQT waived the condition regarding a minimum level of acceptance in the offer. Furthermore, all other conditions for completion of the offer have been satisfied and the offer is now unconditional. The acceptance period for the offer is extended up to and including February 12, 2019 to allow remaining shareholders in Karo Pharma to accept the Offer. Hamilton Advokatbyrå acted as legal advisor while Deloitte AB provided fairness opinion to Karo Pharma. Skandinaviska Enskilda Banken AB (publ.) acted as financial advisor and Jan Jensen, Rikard Stenberg, Johan Thiman, Oscar Liljeson, Peter Svanqvist, Patrik Erblad, David Riihonen, Erik Larsson, Rebecka Tenenbaum, Anders Westling, Petar Bojovic, Gustaf Wiklund and Björn Torsteinsrud of White & Case acted as legal advisors to EQT Partners in connection with the transaction. EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion in January, 2019.
お知らせ • Jul 31+ 1 more updateKaro Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million on May 8, 2020. The transaction is financed by a new loan facility from SEB, Swedbank and DNB NOR. The remaining Pevaryl® brand portfolio generated net sales of around €20 million in 2019. The transaction gives full control to Karo Pharma AB for the Pevaryl® brand portfolio in Europe. No personnel or manufacturing sites are included in the agreement and the technology transfer risks are limited. Johnson & Johnson and Karo Pharma will collaborate to secure a seamless transfer of the portfolio, including relevant approvals. Sawaya Partners, LLC acted as the financial advisor for Karo Pharma AB (publ). Karo Pharma AB (publ) (OM:KARO) completed the acquisition of remaining Pevaryl® brand portfolio from Cilag GmbH International on May 8, 2020.
お知らせ • Jul 21Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021Karo Pharma AB (publ) announced that they will report fiscal year 2020 results on Feb 18, 2021